Please login to the form below

Not currently logged in
Email:
Password:

Reasanz

This page shows the latest Reasanz news and features for those working in and with pharma, biotech and healthcare.

Novartis will file heart failure drug before year-end

Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a ... Novartis is currently conducting a second phase III

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics